WALTHAM, Mass. - Syndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has reported encouraging results from trials of revumenib, its acute leukemia drug candidate. At the European Hematology Association 2024 Congress in Madrid, findings from two trials, BEAT AML and AUGMENT-102, were presented, showcasing the drug's potential in combination with other therapies for treating acute myeloid leukemia (AML).
In the BEAT AML trial, revumenib was tested alongside venetoclax/azacitidine in patients over 60 with newly diagnosed mutant nucleophosmin (mNPM1) or KMT2A-rearranged (KMT2Ar) AML. An impressive 96% composite complete remission rate was observed, with 92% of patients reaching minimal residual disease (MRD) negative status. The trial also reported a 100% estimated 12-month survival rate for the first cohort.
The AUGMENT-102 trial focused on a predominantly pediatric population with relapsed/refractory (R/R) mNPM1, NUP98-rearranged (NUP98r), or KMT2Ar AML. It combined revumenib with fludarabine/cytarabine, resulting in a 52% composite complete remission rate. Furthermore, 71% of patients who achieved CRc and had evaluable data reached MRD negative status, with several proceeding to hematopoietic stem cell transplant.
Safety profiles from both trials suggest that revumenib can be administered effectively without increasing the frequency or severity of adverse events, even in heavily pretreated patients. The results support the continued development of revumenib as a potential treatment option across various acute leukemia settings.
Syndax is preparing for the expected near-term approval of revumenib in the relapsed or refractory setting and plans to initiate a pivotal trial with the BEAT AML combination by the end of 2024. The company is also advancing revumenib as a monotherapy, with its dose currently under FDA review.
These studies are part of Syndax's broader efforts to develop innovative cancer therapies.
The data presented at the EHA Congress is based on a press release statement from Syndax Pharmaceuticals.
In other recent news, Pyxis Oncology and Syndax Pharmaceuticals announced significant additions to their respective boards. Pyxis Oncology appointed Michael A. Metzger, a biopharma industry veteran and current CEO of Syndax Pharmaceuticals. Metzger's appointment comes as Pyxis continues to advance its antibody-drug conjugates and immuno-oncology programs.
Meanwhile, Syndax Pharmaceuticals welcomed Aleksandra Rizo, M.D., Ph.D., to its board. Dr. Rizo's extensive experience in hematology drugs is expected to contribute significantly to Syndax's strategic transition to a commercial-stage organization.
In terms of financial performance, Syndax Pharmaceuticals outlined a robust Q1 2024 performance during its recent earnings call. The company reported a strong cash position of $522 million, expected to last through 2026.
Analysts have been closely monitoring Syndax's progress. The company has been consistently rated "Overweight" by analysts, including Barclays (LON:BARC) Capital Inc. and JPMorgan (NYSE:JPM). Despite negative earnings per share forecasts, the analysts maintain a positive outlook on Syndax's industry due to its promising drug pipeline and strategic financial management.
In the realm of biotechnology, Syndax Pharmaceuticals has emerged as a notable player, especially with its pioneering work on revumenib, a Menin inhibitor, which has been showing significant potential in the treatment of various cancers. The company's drug pipeline is robust, with two significant PDUFA dates on the horizon, potentially leading to market approval.
InvestingPro Insights
As Syndax Pharmaceuticals (NASDAQ: SNDX) continues to make strides in the development of its acute leukemia drug candidate, revumenib, the financial health and market perception of the company remain critical for investors. With a focus on the company's latest performance and future outlook, here are some key insights based on real-time data from InvestingPro and InvestingPro Tips:
InvestingPro data highlights a market capitalization of $1.76 billion for Syndax, reflecting the market's valuation of the company's potential. Despite the challenges faced in profitability, with a negative P/E ratio of -6.38 and an adjusted P/E ratio for the last twelve months as of Q1 2024 at -7.31, the company's strategic moves in advancing revumenib could be a game-changer. Additionally, the company's price to book ratio stands at 3.58, suggesting that investors are willing to pay a premium for what they believe to be a robust pipeline with significant future growth potential.
From the perspective of InvestingPro Tips, Syndax holds more cash than debt on its balance sheet, which is a positive sign for financial stability and future investments in research and development. Moreover, 8 analysts have revised their earnings upwards for the upcoming period, indicating a positive sentiment towards the company's financial prospects. This is particularly relevant as Syndax prepares for pivotal trials and seeks FDA approval for revumenib. However, it's worth noting that analysts do not anticipate the company will be profitable this year, and net income is expected to drop. This information could be crucial for investors considering the long-term value and the risks associated with the company's growth trajectory.
For those interested in a deeper dive into Syndax's financials and future projections, there are additional InvestingPro Tips available, which can be accessed by visiting https://www.investing.com/pro/SNDX. To enhance your research experience, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With numerous tips at your disposal, you can make more informed investment decisions regarding Syndax Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.